Roche’s Mabthera faces cut-price competition in EU
Blockbuster likely to face cheap near-copy for first time.
X
Roche’s Mabthera faces cut-price competition in EU
https://pharmaphorum.com/news/roches-mabthera-faces-cut-price-competition-eu/
CLL
AbbVie’s Venclyxto approved in Europe in CLL
AbbVie blood cancer drug tipped to be a blockbuster.
AbbVie’s CLL drug recommended in Europe
Leukaemia drug likely to get conditional approval.
NICE rejects Roche drug in follicular lymphoma
NICE uncertain over survival data for Gazyvaro and bendamustine.
Novartis’ Arzerra gains CLL approval
Development partner Genmab says drug approved in relapsed disease.
UK grants patients early access to AbbVie/Roche leukaemia drug
Venetoclax still under review in Europe.
